Abstract | OBJECTIVE: METHODS: Two phase I studies were conducted to evaluate the safety and pharmacokinetics of single and multiple doses of arzoxifene. In addition, two multi-institutional phase II trials have been completed on 100 women with metastatic or recurrent endometrial cancer. RESULTS: No serious adverse events were observed in the single-dose phase I study, the principal side effect being hot flashes in 5/15 healthy volunteers. In the second phase I study, conducted in 32 women with metastatic breast cancer, one patient had a serious, possibly drug-related adverse reaction ( pulmonary embolism). The two multi-institutional trials demonstrated significant activity at 20 mg/day in patients with metastatic or recurrent endometrial cancer. Observed clinical response rates were 25 and 31%, with a median response duration of 19.3 and 13.9 months, respectively. Progression of the disease was stabilized in a substantial number of women. Toxicity was mild, except for two cases of pulmonary embolism that might have been drug related. CONCLUSIONS: Further investigation is warranted to verify these preliminary response rates and the clinical significance of the stable disease cases, to compare clinical outcomes with those in progestin-treated women, and to elucidate the mechanisms of SERM action in this disease.
|
Authors | Thomas W Burke, Cheryl L Walker |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 90
Issue 2 Pt 2
Pg. S40-6
(Aug 2003)
ISSN: 0090-8258 [Print] United States |
PMID | 12928005
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Piperidines
- Selective Estrogen Receptor Modulators
- Thiophenes
- LY 353381
|
Topics |
- Antineoplastic Agents, Hormonal
(adverse effects, pharmacokinetics, therapeutic use)
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Endometrial Neoplasms
(drug therapy, metabolism)
- Female
- Humans
- Multicenter Studies as Topic
- Piperidines
(adverse effects, pharmacokinetics, therapeutic use)
- Selective Estrogen Receptor Modulators
(adverse effects, pharmacokinetics, therapeutic use)
- Thiophenes
(adverse effects, pharmacokinetics, therapeutic use)
|